We are live on ! Find out more
UBS Group

UBS Group Portfolio holdings

AUM $666B
1-Year Est. Return 30.12%
 

UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.

This Fund
S&P 500
This Quarter Est. Return
+8.15%
1 Year Est. Return
+30.12%
3 Year Est. Return
+86.21%
5 Year Est. Return
+101.56%
10 Year Est. Return
+367.78%
AUM
$287B
AUM Growth
+$27.6B
Cap. Flow
+$6.59B
Cap. Flow %
2.29%
Top 10 Hldgs %
12.98%
Holding
8,864
New
808
Increased
4,306
Reduced
2,684
Closed
688

Sector Composition

Rank Sector Weight
1 Technology 9.82%
2 Financials 7.38%
3 Healthcare 6.65%
4 Consumer Discretionary 5.46%
5 Industrials 5.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MYND
7076
Mynd.ai
MYND
$17.4M
$14K ﹤0.01%
254
+148
+140% +$8.85K
ONCY
7077
Oncolytics Biotech
ONCY
$95.6M
$14K ﹤0.01%
3,000
+2,256
+303% +$2.55K
PDSB icon
7078
PDS Biotechnology
PDSB
$41.8M
$14K ﹤0.01%
+5,450
New +$15.5K
RLJ.PRA icon
7079
RLJ Lodging Trust $1.95 Series A Preferred Stock
RLJ.PRA
$322M
$14K ﹤0.01%
500
-10,578
-95% -$295K
FLNA
7080
Filana Therapeutics
FLNA
$46.3M
$14K ﹤0.01%
2,707
+2,417
+833% +$4.17K
SDCI icon
7081
USCF SummerHaven Dynamic Commodity Strategy No K-1 Fund
SDCI
$567M
$14K ﹤0.01%
777
+212
+38% +$3.81K
SDS icon
7082
ProShares UltraShort S&P500
SDS
$394M
$14K ﹤0.01%
22
-292
-93% -$201K
SGMA
7083
DELISTED
Sigmatron International
SGMA
$14K ﹤0.01%
3,384
+2,400
+244% +$10.2K
TYO icon
7084
Direxion Daily 7-10 Year Treasury Bear 3X ETF
TYO
$12.4M
$14K ﹤0.01%
1,262
+462
+58% +$5K
VANI icon
7085
Vivani Medical
VANI
$117M
$14K ﹤0.01%
102
+85
+500% +$1.67K
VIDI icon
7086
Vident International Equity Strategy
VIDI
$443M
$14K ﹤0.01%
561
-1,380
-71% -$33.7K
VTGN icon
7087
VistaGen Therapeutics
VTGN
$12.6M
$14K ﹤0.01%
670
-159
-19% -$4.02K
XBIO icon
7088
Xenetic Biosciences
XBIO
$6.53M
$14K ﹤0.01%
976
+699
+252% +$8.88K
AIFC
7089
AI Financial Corp
AIFC
$56.8M
$14K ﹤0.01%
+4,891
New +$13.8K
ATYR
7090
aTyr Pharma
ATYR
$49.2M
$14K ﹤0.01%
+3,448
New +$13.3K
AIOT
7091
PowerFleet Inc
AIOT
$554M
$14K ﹤0.01%
+2,087
New +$12.6K
LUMO
7092
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$14K ﹤0.01%
603
-304
-34% -$4.34K
BTEC
7093
DELISTED
Principal Exchange-Traded Funds Principal Healthcare Innovators ETF
BTEC
$14K ﹤0.01%
357
+43
+14% +$1.51K
KFYP
7094
DELISTED
KraneShares CICC China Leaders 100 Index ETF
KFYP
$14K ﹤0.01%
485
-195
-29% -$5.32K
SNLN
7095
DELISTED
Highland/iBoxx Senior Loan ETF
SNLN
$14K ﹤0.01%
822
-115
-12% -$2K
TA
7096
DELISTED
TravelCenters of America LLC
TA
$14K ﹤0.01%
834
OPNT
7097
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$14K ﹤0.01%
+964
New +$14.1K
CXDC
7098
DELISTED
China XD Plastics Company Limited
CXDC
$14K ﹤0.01%
7,543
+6,543
+654% +$13K
CCX.U
7099
DELISTED
Churchill Capital Corp II
CCX.U
$14K ﹤0.01%
1,343
THBRU
7100
DELISTED
Thunder Bridge Acquisition II, Ltd. Units
THBRU
$14K ﹤0.01%
1,300
-900
-41% -$9.28K

Similar funds

UBS Group's Q4 2019 Portfolio in Review

As of Q4 2019, UBS Group held 8,864 positions worth $287B, up 11% from $260B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

UBS Group's Q4 2019 filing shows 808 new, 4,306 increased, 2,684 reduced and 688 closed positions. Its largest new stake was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.3B.

By sector, the portfolio is most concentrated in Technology at 9.8% of assets, up from 9.5% a quarter earlier, followed by Financials and Healthcare.

  • UBS Group's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M.
  • UBS Group added most to UBS Group in Q4 2019, an estimated $1.48B increase.
  • UBS Group's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.3B.
  • UBS Group fully exited Altaba Inc in Q4 2019, selling an estimated $759M.
  • UBS Group's ten largest holdings make up 13% of its $287B portfolio in Q4 2019.
  • UBS Group opened 808 new positions and closed 688 in Q4 2019.
  • UBS Group's portfolio value rose 11% quarter-over-quarter to $287B.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.